Early immunotherapy aids in treating potentially fatal fungal pneumonias in preclinical models

A new study led by researchers at The University of Texas MD Anderson Cancer Center has shown that early administration of immunotherapy with standard antifungal treatment improved outcomes and largely alleviated immune system paralysis caused by fungal lung infections in preclinical models. These findings could herald new clinically relevant strategies for treating a variety of life-threatening invasive fungal pneumonias, which disproportionately affect immunocompromised cancer patients.